Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1–infected subjects with genotypic evidence of RAL re...

Descripción completa

Detalles Bibliográficos
Autores principales: Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563307/
https://www.ncbi.nlm.nih.gov/pubmed/23225901
http://dx.doi.org/10.1093/infdis/jis750
_version_ 1782258172584525824
author Eron, Joseph J.
Clotet, Bonaventura
Durant, Jacques
Katlama, Christine
Kumar, Princy
Lazzarin, Adriano
Poizot-Martin, Isabelle
Richmond, Gary
Soriano, Vincent
Ait-Khaled, Mounir
Fujiwara, Tamio
Huang, Jenny
Min, Sherene
Vavro, Cindy
Yeo, Jane
Walmsley, Sharon L.
Cox, Joseph
Reynes, Jacques
Morlat, Philippe
Vittecoq, Daniel
Livrozet, Jean-Michel
Fernández, Pompeyo Viciana
Gatell, Jose M.
DeJesus, Edwin
DeVente, Jerome
Lalezari, Jacob P.
McCurdy, Lewis H.
Sloan, Louis A.
Young, Benjamin
LaMarca, Anthony
Hawkins, Trevor
author_facet Eron, Joseph J.
Clotet, Bonaventura
Durant, Jacques
Katlama, Christine
Kumar, Princy
Lazzarin, Adriano
Poizot-Martin, Isabelle
Richmond, Gary
Soriano, Vincent
Ait-Khaled, Mounir
Fujiwara, Tamio
Huang, Jenny
Min, Sherene
Vavro, Cindy
Yeo, Jane
Walmsley, Sharon L.
Cox, Joseph
Reynes, Jacques
Morlat, Philippe
Vittecoq, Daniel
Livrozet, Jean-Michel
Fernández, Pompeyo Viciana
Gatell, Jose M.
DeJesus, Edwin
DeVente, Jerome
Lalezari, Jacob P.
McCurdy, Lewis H.
Sloan, Louis A.
Young, Benjamin
LaMarca, Anthony
Hawkins, Trevor
author_sort Eron, Joseph J.
collection PubMed
description Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1–infected subjects with genotypic evidence of RAL resistance. Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log(10) copies/mL from baseline or was <400 copies/mL. Results. A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen. Conclusion. Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL.
format Online
Article
Text
id pubmed-3563307
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-35633072013-02-04 Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study Eron, Joseph J. Clotet, Bonaventura Durant, Jacques Katlama, Christine Kumar, Princy Lazzarin, Adriano Poizot-Martin, Isabelle Richmond, Gary Soriano, Vincent Ait-Khaled, Mounir Fujiwara, Tamio Huang, Jenny Min, Sherene Vavro, Cindy Yeo, Jane Walmsley, Sharon L. Cox, Joseph Reynes, Jacques Morlat, Philippe Vittecoq, Daniel Livrozet, Jean-Michel Fernández, Pompeyo Viciana Gatell, Jose M. DeJesus, Edwin DeVente, Jerome Lalezari, Jacob P. McCurdy, Lewis H. Sloan, Louis A. Young, Benjamin LaMarca, Anthony Hawkins, Trevor J Infect Dis Major Articles and Brief Reports Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1–infected subjects with genotypic evidence of RAL resistance. Methods. Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort II) while continuing a failing regimen (without RAL) through day 10, after which the background regimen was optimized, when feasible, for cohort I, and at least 1 fully active drug was mandated for cohort II. The primary efficacy end point was the proportion of subjects on day 11 in whom the plasma HIV-1 RNA load decreased by ≥0.7 log(10) copies/mL from baseline or was <400 copies/mL. Results. A rapid antiviral response was observed. More subjects achieved the primary end point in cohort II (23 of 24 [96%]), compared with cohort I (21 of 27 [78%]) at day 11. At week 24, 41% and 75% of subjects had an HIV-1 RNA load of <50 copies/mL in cohorts I and II, respectively. Further integrase genotypic evolution was uncommon. Dolutegravir had a good, similar safety profile with each dosing regimen. Conclusion. Dolutegravir 50 mg twice daily with an optimized background provided greater and more durable benefit than the once-daily regimen. These data are the first clinical demonstration of the activity of any integrase inhibitor in subjects with HIV-1 resistant to RAL. Oxford University Press 2013-03-01 2012-12-07 /pmc/articles/PMC3563307/ /pubmed/23225901 http://dx.doi.org/10.1093/infdis/jis750 Text en © The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Major Articles and Brief Reports
Eron, Joseph J.
Clotet, Bonaventura
Durant, Jacques
Katlama, Christine
Kumar, Princy
Lazzarin, Adriano
Poizot-Martin, Isabelle
Richmond, Gary
Soriano, Vincent
Ait-Khaled, Mounir
Fujiwara, Tamio
Huang, Jenny
Min, Sherene
Vavro, Cindy
Yeo, Jane
Walmsley, Sharon L.
Cox, Joseph
Reynes, Jacques
Morlat, Philippe
Vittecoq, Daniel
Livrozet, Jean-Michel
Fernández, Pompeyo Viciana
Gatell, Jose M.
DeJesus, Edwin
DeVente, Jerome
Lalezari, Jacob P.
McCurdy, Lewis H.
Sloan, Louis A.
Young, Benjamin
LaMarca, Anthony
Hawkins, Trevor
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
title Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
title_full Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
title_fullStr Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
title_full_unstemmed Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
title_short Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
title_sort safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant hiv type 1 infection: 24-week results of the viking study
topic Major Articles and Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3563307/
https://www.ncbi.nlm.nih.gov/pubmed/23225901
http://dx.doi.org/10.1093/infdis/jis750
work_keys_str_mv AT eronjosephj safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT clotetbonaventura safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT durantjacques safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT katlamachristine safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT kumarprincy safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT lazzarinadriano safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT poizotmartinisabelle safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT richmondgary safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT sorianovincent safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT aitkhaledmounir safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT fujiwaratamio safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT huangjenny safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT minsherene safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT vavrocindy safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT yeojane safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT walmsleysharonl safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT coxjoseph safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT reynesjacques safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT morlatphilippe safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT vittecoqdaniel safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT livrozetjeanmichel safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT fernandezpompeyoviciana safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT gatelljosem safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT dejesusedwin safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT deventejerome safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT lalezarijacobp safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT mccurdylewish safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT sloanlouisa safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT youngbenjamin safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT lamarcaanthony safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy
AT hawkinstrevor safetyandefficacyofdolutegravirintreatmentexperiencedsubjectswithraltegravirresistanthivtype1infection24weekresultsofthevikingstudy